Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
To investigate whether a Caduet based treatment strategy might result in greater reduction in
total cardiovascular risk as compared to usual care in subjects with hypertension and
additional risk factors.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Amlodipine Amlodipine, atorvastatin drug combination Atorvastatin Atorvastatin Calcium Calcium